Lake Street Capital Begins Coverage on Organogenesis (NASDAQ:ORGO)

Lake Street Capital started coverage on shares of Organogenesis (NASDAQ:ORGO) in a research note published on Friday, Marketbeat Ratings reports. The firm issued a buy rating and a $5.00 price target on the stock.

Separately, Cantor Fitzgerald reiterated an overweight rating and set a $5.00 price objective on shares of Organogenesis in a research note on Friday, March 1st.

Organogenesis Price Performance

ORGO opened at $2.80 on Friday. The company has a quick ratio of 2.41, a current ratio of 2.74 and a debt-to-equity ratio of 0.22. Organogenesis has a 52-week low of $1.96 and a 52-week high of $4.70. The company has a 50 day moving average of $2.63 and a two-hundred day moving average of $3.12. The company has a market cap of $371.20 million, a P/E ratio of 70.02 and a beta of 1.66.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. Organogenesis had a net margin of 1.34% and a return on equity of 2.11%. The company had revenue of $109.98 million during the quarter, compared to the consensus estimate of $100.44 million. During the same period in the previous year, the firm earned ($0.02) earnings per share. On average, analysts expect that Organogenesis will post -0.05 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ORGO. Tower Research Capital LLC TRC lifted its position in shares of Organogenesis by 94.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,663 shares of the company’s stock worth $27,000 after purchasing an additional 3,235 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in Organogenesis in the fourth quarter valued at $43,000. Palumbo Wealth Management LLC acquired a new stake in Organogenesis in the fourth quarter valued at $46,000. Barclays PLC raised its holdings in Organogenesis by 80.6% in the third quarter. Barclays PLC now owns 25,276 shares of the company’s stock valued at $80,000 after acquiring an additional 11,284 shares in the last quarter. Finally, Capital Square LLC raised its holdings in Organogenesis by 23.8% in the fourth quarter. Capital Square LLC now owns 20,450 shares of the company’s stock valued at $84,000 after acquiring an additional 3,930 shares in the last quarter. 49.57% of the stock is owned by institutional investors and hedge funds.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.